MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $5.38 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,701 shares of the medical instruments supplier’s stock after buying an additional 861 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Becton, Dickinson and Company were worth $5,377,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB increased its stake in Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock valued at $39,951,000 after buying an additional 20,859 shares during the last quarter. Busey Bank lifted its position in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock worth $15,031,000 after buying an additional 2,399 shares in the last quarter. Swedbank AB boosted its stake in shares of Becton, Dickinson and Company by 1.0% in the 4th quarter. Swedbank AB now owns 152,293 shares of the medical instruments supplier’s stock worth $34,551,000 after buying an additional 1,455 shares during the last quarter. Finally, Phraction Management LLC grew its holdings in shares of Becton, Dickinson and Company by 7.2% in the fourth quarter. Phraction Management LLC now owns 47,021 shares of the medical instruments supplier’s stock valued at $10,668,000 after acquiring an additional 3,138 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $175.37 on Monday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The business’s fifty day simple moving average is $203.61 and its two-hundred day simple moving average is $220.72. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The company has a market cap of $50.26 billion, a price-to-earnings ratio of 29.13, a P/E/G ratio of 1.63 and a beta of 0.31.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the previous year, the firm posted $3.17 EPS. The firm’s revenue was up 4.5% on a year-over-year basis. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a share buyback plan on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.37%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company’s payout ratio is 79.39%.

Insider Activity

In related news, EVP Richard Byrd sold 459 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the sale, the executive vice president now owns 6,952 shares of the company’s stock, valued at approximately $1,598,960. This trade represents a 6.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 479 shares of the company’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares of the company’s stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,878 shares of company stock valued at $636,393 in the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Raymond James lowered Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Morgan Stanley decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price on the stock. in a research note on Friday, May 2nd. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Finally, Piper Sandler downgraded Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average target price of $231.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.